MedOptions is growing. The nation’s leading provider of behavioral health services to skilled nursing and assisted living facilities continues to expand and has local opportunities for nurse practitioners to join our team of 800 clinicians and support staff. MedOptions partners with skilled nursing and assisted living facilities across the nation to provide expert behavioral health services, improving the overall mental health in elderly patients through the use of memory care evaluations, medication management, and behavioral interventions. Our multidisciplinary team consists of psychiatrists, nurse practitioners, clinical psychologists and clinical social workers. They are experienced in dementia care and Alzheimer’s care, long term behavioral health care in elderly populations, and memory care services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More

MEDICAL

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

news image

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

news image

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More

MEDTECH, INDUSTRIAL IMPACT

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

news image

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More
news image

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More
news image

MEDICAL

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More
news image

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More
news image

MEDTECH, INDUSTRIAL IMPACT

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us